Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Immunocore

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Select Advanced Solid Tumors

Treatments: Drug: Atezolizumab; Drug: IMC-C103C

Study type: Interventional

Funder types: Industry

Identifiers

NCT03973333

IMC-C103C-101

Details and patient eligibility

About

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

Full description

The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable tumors which include select Advanced Solid Tumors and will be conducted in two phases.

1. To identify the maximum tolerated dose (MTD) and/or expansion dose of IMC-C103C as a single agent administered intravenously (IV) and subcutaneously (SC) once weekly (Q1W) and administered Q1W in combination with once every 3 weeks (Q3W) atezolizumab.
2. To assess the preliminary anti-tumor activity of IMC-C103C in one or more selected indications, as a single agent administered Q1W.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. HLA-A*02:01 positive
2. MAGE-A4 positive tumor
3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
4. Selected advanced solid tumors
5. Relapsed from, refractory to, or intolerant of standard therapy
6. Measurable disease per RECIST v1.1 (expansion)
7. If applicable, must agree to use highly effective contraception

Exclusion criteria

1. Symptomatic or untreated central nervous system metastasis
2. Inadequate washout from prior anticancer therapy
3. Significant ongoing toxicity from prior anticancer treatment
4. Impaired baseline organ function as evaluated by out-of-range laboratory values
5. Clinically significant cardiac disease
6. Active infection requiring systemic antibiotic therapy
7. Known history of human immunodeficiency virus (HIV)
8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)
9. Ongoing treatment with systemic steroids or other immunosuppressive therapies
10. Significant secondary malignancy
11. Pregnancy or lactation

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

0 participants in 4 patient groups

IMC-C103C - Monotherapy IV dose escalation

Experimental group

Description:

n= approximately 50 patients to establish the MTD/expansion dose

Treatment:

Drug: IMC-C103C

Drug: IMC-C103C

IMC-C103C and atezolizumab dose escalation

Experimental group

Description:

n=approximately 12 patients to establish the MTD/expansion dose

Treatment:

Drug: IMC-C103C

Drug: IMC-C103C

Drug: Atezolizumab

IMC-C103C - expansion

Experimental group

Description:

Patients will be enrolled n=9-24 per expansion cohort (up to 4 total): metastatic/unresectable tumors of interest patients treated at the expansion dose of IMC-C103C to assess preliminary anti-tumor efficacy

Treatment:

Drug: IMC-C103C

Drug: IMC-C103C

IMC-C103C monotherapy SC dose escalation

Experimental group

Description:

Patients will be enrolled n=9-12 to establish the MTD/expansion dose

Treatment:

Drug: IMC-C103C

Drug: IMC-C103C